110 related articles for article (PubMed ID: 16557009)
1. [Therapeutic inhibition of Epstein-Barr virus-associated tumor cell growth by dominant-negative EBNA1].
Imai S; Kuroda M; Yamashita R; Ishiura Y
Uirusu; 2005 Dec; 55(2):239-49. PubMed ID: 16557009
[TBL] [Abstract][Full Text] [Related]
2. Eradication of Epstein-Barr virus episome and associated inhibition of infected tumor cell growth by adenovirus vector-mediated transduction of dominant-negative EBNA1.
Nasimuzzaman M; Kuroda M; Dohno S; Yamamoto T; Iwatsuki K; Matsuzaki S; Mohammad R; Kumita W; Mizuguchi H; Hayakawa T; Nakamura H; Taguchi T; Wakiguchi H; Imai S
Mol Ther; 2005 Apr; 11(4):578-90. PubMed ID: 15771960
[TBL] [Abstract][Full Text] [Related]
3. Suppression of Epstein-Barr nuclear antigen 1 (EBNA1) by RNA interference inhibits proliferation of EBV-positive Burkitt's lymphoma cells.
Hong M; Murai Y; Kutsuna T; Takahashi H; Nomoto K; Cheng CM; Ishizawa S; Zhao QL; Ogawa R; Harmon BV; Tsuneyama K; Takano Y
J Cancer Res Clin Oncol; 2006 Jan; 132(1):1-8. PubMed ID: 16180023
[TBL] [Abstract][Full Text] [Related]
4. Structural and Functional Basis for an EBNA1 Hexameric Ring in Epstein-Barr Virus Episome Maintenance.
Deakyne JS; Malecka KA; Messick TE; Lieberman PM
J Virol; 2017 Oct; 91(19):. PubMed ID: 28701406
[TBL] [Abstract][Full Text] [Related]
5. [Epstein-Barr Virus Genome Replication as a Molecular Target for Cancer Therapy].
Noguchi K
Yakugaku Zasshi; 2019; 139(1):63-67. PubMed ID: 30606931
[TBL] [Abstract][Full Text] [Related]
6. Identification of MEF2B, EBF1, and IL6R as Direct Gene Targets of Epstein-Barr Virus (EBV) Nuclear Antigen 1 Critical for EBV-Infected B-Lymphocyte Survival.
Tempera I; De Leo A; Kossenkov AV; Cesaroni M; Song H; Dawany N; Showe L; Lu F; Wikramasinghe P; Lieberman PM
J Virol; 2016 Jan; 90(1):345-55. PubMed ID: 26468528
[TBL] [Abstract][Full Text] [Related]
7. HCF1 and OCT2 Cooperate with EBNA1 To Enhance OriP-Dependent Transcription and Episome Maintenance of Latent Epstein-Barr Virus.
Dheekollu J; Wiedmer A; Sentana-Lledo D; Cassel J; Messick T; Lieberman PM
J Virol; 2016 Jun; 90(11):5353-5367. PubMed ID: 27009953
[TBL] [Abstract][Full Text] [Related]
8. Epstein-barr virus nuclear antigen 1 sequences in endemic and sporadic Burkitt's lymphoma reflect virus strains prevalent in different geographic areas.
Habeshaw G; Yao QY; Bell AI; Morton D; Rickinson AB
J Virol; 1999 Feb; 73(2):965-75. PubMed ID: 9882297
[TBL] [Abstract][Full Text] [Related]
9. Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo.
Hochberg D; Middeldorp JM; Catalina M; Sullivan JL; Luzuriaga K; Thorley-Lawson DA
Proc Natl Acad Sci U S A; 2004 Jan; 101(1):239-44. PubMed ID: 14688409
[TBL] [Abstract][Full Text] [Related]
10. siRNAs against the Epstein Barr virus latency replication factor, EBNA1, inhibit its function and growth of EBV-dependent tumor cells.
Yin Q; Flemington EK
Virology; 2006 Mar; 346(2):385-93. PubMed ID: 16343579
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus-encoded EBNA1 and ZEBRA: targets for therapeutic strategies against EBV-carrying cancers.
Daskalogianni C; Pyndiah S; Apcher S; Mazars A; Manoury B; Ammari N; Nylander K; Voisset C; Blondel M; Fåhraeus R
J Pathol; 2015 Jan; 235(2):334-41. PubMed ID: 25186125
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus provides a survival factor to Burkitt's lymphomas.
Kennedy G; Komano J; Sugden B
Proc Natl Acad Sci U S A; 2003 Nov; 100(24):14269-74. PubMed ID: 14603034
[TBL] [Abstract][Full Text] [Related]
13. Targeted disruption of EBNA1 in EBV-infected cells attenuated cell growth.
Noh KW; Park J; Kang MS
BMB Rep; 2016 Apr; 49(4):226-31. PubMed ID: 26879316
[TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr virus nuclear antigen 2 (EBNA2) gene deletion is consistently linked with EBNA3A, -3B, and -3C expression in Burkitt's lymphoma cells and with increased resistance to apoptosis.
Kelly GL; Milner AE; Tierney RJ; Croom-Carter DS; Altmann M; Hammerschmidt W; Bell AI; Rickinson AB
J Virol; 2005 Aug; 79(16):10709-17. PubMed ID: 16051863
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus nuclear antigen 1 (EBNA1) induced cytotoxicity in epithelial cells is associated with EBNA1 degradation and processing.
Jones RJ; Smith LJ; Dawson CW; Haigh T; Blake NW; Young LS
Virology; 2003 Sep; 313(2):663-76. PubMed ID: 12954232
[TBL] [Abstract][Full Text] [Related]
16. Carcinoma-risk variant of EBNA1 deregulates Epstein-Barr Virus episomal latency.
Dheekollu J; Malecka K; Wiedmer A; Delecluse HJ; Chiang AK; Altieri DC; Messick TE; Lieberman PM
Oncotarget; 2017 Jan; 8(5):7248-7264. PubMed ID: 28077791
[TBL] [Abstract][Full Text] [Related]
17. The interaction between Vav1 and EBNA1 promotes survival of Burkitt's lymphoma cells by down-regulating the expression of Bim.
Wang R; Wang J; Zhang N; Wan Y; Liu Y; Zhang L; Pan S; Zhang C; Zhang H; Cao Y
Biochem Biophys Res Commun; 2019 Apr; 511(4):787-793. PubMed ID: 30833082
[TBL] [Abstract][Full Text] [Related]
18. Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells.
Kelly GL; Milner AE; Baldwin GS; Bell AI; Rickinson AB
Proc Natl Acad Sci U S A; 2006 Oct; 103(40):14935-40. PubMed ID: 17001014
[TBL] [Abstract][Full Text] [Related]
19. EBP2, a human protein that interacts with sequences of the Epstein-Barr virus nuclear antigen 1 important for plasmid maintenance.
Shire K; Ceccarelli DF; Avolio-Hunter TM; Frappier L
J Virol; 1999 Apr; 73(4):2587-95. PubMed ID: 10074103
[TBL] [Abstract][Full Text] [Related]
20. Baicalein inhibits growth of Epstein-Barr virus-positive nasopharyngeal carcinoma by repressing the activity of EBNA1 Q-promoter.
Zhang Y; Wang H; Liu Y; Wang C; Wang J; Long C; Guo W; Sun X
Biomed Pharmacother; 2018 Jun; 102():1003-1014. PubMed ID: 29710517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
